These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 16340021

  • 1. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
    Chan DT, Poon WS, Chan YL, Ng HK.
    Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
    [Abstract] [Full Text] [Related]

  • 2. [Favourable result for temozolomide in recurrent high-grade glioma].
    Taal W, van der Rijt CD, Sillevis Smitt PA, Kros JM, van Heuvel I, Enting RH, van den Bent MJ.
    Ned Tijdschr Geneeskd; 2005 Jun 18; 149(25):1393-9. PubMed ID: 15997692
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
    Duerinck J, Du Four S, Sander W, Van Binst AM, Everaert H, Michotte A, Hau P, Neyns B.
    Anticancer Res; 2015 Oct 18; 35(10):5551-7. PubMed ID: 26408725
    [Abstract] [Full Text] [Related]

  • 7. [Temozolomide in the treatment of recurrent malignant glioma].
    Kobayashi H, Sawamura Y, Ishii N, Murata J, Iwasaki Y.
    No Shinkei Geka; 2006 Dec 18; 34(12):1241-7. PubMed ID: 17154070
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Temozolomide chemotherapy in patients with recurrent malignant gliomas.
    Yang SH, Kim MK, Lee TK, Lee KS, Jeun SS, Park CK, Kang JK, Kim MC, Hong YK.
    J Korean Med Sci; 2006 Aug 18; 21(4):739-44. PubMed ID: 16891823
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
    Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F.
    J Clin Oncol; 2001 May 01; 19(9):2449-55. PubMed ID: 11331324
    [Abstract] [Full Text] [Related]

  • 14. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
    Brandes AA, Ermani M, Basso U, Amistà P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S.
    Ann Oncol; 2001 Feb 01; 12(2):255-7. PubMed ID: 11300334
    [Abstract] [Full Text] [Related]

  • 15. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
    Freyschlag CF, Smolczyk DR, Janzen E, Schmieder K, Thomé C, Lohr F, Wenz F, Weiss C, Tuettenberg J, Seiz M.
    Anticancer Res; 2011 Nov 01; 31(11):3873-7. PubMed ID: 22110212
    [Abstract] [Full Text] [Related]

  • 16. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):511-9. PubMed ID: 16168843
    [Abstract] [Full Text] [Related]

  • 17. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC, Tsao-Wei DD.
    Cancer; 2004 Mar 15; 100(6):1213-20. PubMed ID: 15022289
    [Abstract] [Full Text] [Related]

  • 18. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
    Perry JR, Rizek P, Cashman R, Morrison M, Morrison T.
    Cancer; 2008 Oct 15; 113(8):2152-7. PubMed ID: 18756530
    [Abstract] [Full Text] [Related]

  • 19. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
    Neyns B, Chaskis C, Joosens E, Menten J, D'Hondt L, Branle F, Sadones J, Michotte A.
    Cancer Invest; 2008 Oct 15; 26(3):269-77. PubMed ID: 18317968
    [Abstract] [Full Text] [Related]

  • 20. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S.
    Ann Oncol; 2001 Feb 15; 12(2):259-66. PubMed ID: 11300335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.